S&P 500   3,985.01 (+0.85%)
DOW   32,412.27 (+0.52%)
QQQ   308.50 (+0.83%)
AAPL   158.61 (+0.77%)
MSFT   271.64 (-0.22%)
META   200.66 (+1.44%)
GOOGL   104.74 (+3.48%)
AMZN   99.59 (+1.92%)
TSLA   196.04 (+6.98%)
NVDA   260.45 (+0.56%)
NIO   9.26 (+5.83%)
BABA   83.43 (+3.00%)
AMD   95.45 (-1.40%)
T   18.50 (+0.05%)
F   11.75 (+5.10%)
MU   58.42 (+1.35%)
CGC   1.98 (+6.45%)
GE   92.60 (+2.98%)
DIS   96.40 (+2.31%)
AMC   4.42 (+3.51%)
PFE   40.42 (-0.96%)
PYPL   75.84 (+3.59%)
NFLX   305.61 (+0.16%)
S&P 500   3,985.01 (+0.85%)
DOW   32,412.27 (+0.52%)
QQQ   308.50 (+0.83%)
AAPL   158.61 (+0.77%)
MSFT   271.64 (-0.22%)
META   200.66 (+1.44%)
GOOGL   104.74 (+3.48%)
AMZN   99.59 (+1.92%)
TSLA   196.04 (+6.98%)
NVDA   260.45 (+0.56%)
NIO   9.26 (+5.83%)
BABA   83.43 (+3.00%)
AMD   95.45 (-1.40%)
T   18.50 (+0.05%)
F   11.75 (+5.10%)
MU   58.42 (+1.35%)
CGC   1.98 (+6.45%)
GE   92.60 (+2.98%)
DIS   96.40 (+2.31%)
AMC   4.42 (+3.51%)
PFE   40.42 (-0.96%)
PYPL   75.84 (+3.59%)
NFLX   305.61 (+0.16%)
S&P 500   3,985.01 (+0.85%)
DOW   32,412.27 (+0.52%)
QQQ   308.50 (+0.83%)
AAPL   158.61 (+0.77%)
MSFT   271.64 (-0.22%)
META   200.66 (+1.44%)
GOOGL   104.74 (+3.48%)
AMZN   99.59 (+1.92%)
TSLA   196.04 (+6.98%)
NVDA   260.45 (+0.56%)
NIO   9.26 (+5.83%)
BABA   83.43 (+3.00%)
AMD   95.45 (-1.40%)
T   18.50 (+0.05%)
F   11.75 (+5.10%)
MU   58.42 (+1.35%)
CGC   1.98 (+6.45%)
GE   92.60 (+2.98%)
DIS   96.40 (+2.31%)
AMC   4.42 (+3.51%)
PFE   40.42 (-0.96%)
PYPL   75.84 (+3.59%)
NFLX   305.61 (+0.16%)
S&P 500   3,985.01 (+0.85%)
DOW   32,412.27 (+0.52%)
QQQ   308.50 (+0.83%)
AAPL   158.61 (+0.77%)
MSFT   271.64 (-0.22%)
META   200.66 (+1.44%)
GOOGL   104.74 (+3.48%)
AMZN   99.59 (+1.92%)
TSLA   196.04 (+6.98%)
NVDA   260.45 (+0.56%)
NIO   9.26 (+5.83%)
BABA   83.43 (+3.00%)
AMD   95.45 (-1.40%)
T   18.50 (+0.05%)
F   11.75 (+5.10%)
MU   58.42 (+1.35%)
CGC   1.98 (+6.45%)
GE   92.60 (+2.98%)
DIS   96.40 (+2.31%)
AMC   4.42 (+3.51%)
PFE   40.42 (-0.96%)
PYPL   75.84 (+3.59%)
NFLX   305.61 (+0.16%)
CVE:RX

BioSyent - RX Stock Forecast, Price & News

C$7.33
+0.05 (+0.69%)
(As of 03/21/2023 01:14 PM ET)
Add
Compare
Today's Range
C$7.33
▼
C$7.33
50-Day Range
C$7.14
▼
C$7.50
52-Week Range
C$6.24
▼
C$10.00
Volume
200 shs
Average Volume
2,196 shs
Market Capitalization
C$88.69 million
P/E Ratio
14.96
Dividend Yield
2.18%
Price Target
N/A

RX stock logo

About BioSyent (CVE:RX) Stock

BioSyent Inc., a specialty pharmaceutical company, sources, acquires or in-licenses, develops, and sells pharmaceutical and other healthcare products in Canada and internationally. Its products include FeraMAX 150, an oral hematinic; FeraMAX Powder, a water soluble oral iron supplement, which helps the body form red blood cells; and FeraMAX Pd Therapeutic 150 for the prevention and treatment of iron deficiency anemia. It also offers Cathejell, a product indicated for surface anesthesia and lubrication during various procedures, including cystoscopy, catheterization, endourethral operation, endoscopy, proctoscopy, rectoscopy, and tracheal intubation, as well as used for the symptomatic treatment of pain in connection with cystitis and urethritis; RepaGyn, a vaginal suppository for the healing of the vaginal mucosa, as well as for the treatment of vaginal dryness caused by menopause, stress, and chemotherapy; and Proktis-M, a rectal suppository for the healing of the anus and rectum. In addition, it provides Combogesic for moderate acute pain and reduction of fever in adults; Protect-It, a non-chemical food-safe grain insecticide product used as a preventative treatment against insect infestations in stored grains; and Tibella, a hormone replacement therapy to treat vasomotor symptoms due to estrogen deficiency. The company sells its products through wholesalers and retail pharmacy chains. The company was formerly known as Hedley Technologies Inc. and changed its name to BioSyent Inc. in June 2006 to reflect its forward focus on the pharmaceutical market. BioSyent Inc. was incorporated in 2006 and is headquartered in Mississauga, Canada.

Receive RX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter.

RX Stock News Headlines

December 29, 2022 | nz.finance.yahoo.com
A Look At The Fair Value Of BioSyent Inc. (CVE:RX)
December 14, 2022 | finance.yahoo.com
BioSyent Signs Exclusive Agreement for Oncology Supportive Care Product
March 21, 2023 | PressReach (Ad)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
December 4, 2022 | finance.yahoo.com
Shareholders in BioSyent (CVE:RX) are in the red if they invested five years ago
November 17, 2022 | finanznachrichten.de
BioSyent Inc.: BioSyent Releases Q3 and YTD 2022 Financial Results
October 17, 2022 | finance.yahoo.com
Are BioSyent Inc.'s (CVE:RX) Fundamentals Good Enough to Warrant Buying Given The Stock's Recent Weakness?
October 12, 2022 | finance.yahoo.com
BioSyent Initiates First Dividend
September 18, 2022 | reuters.com
RX.V - Biosyent Inc | Stock Price & Latest News | Reuters
March 21, 2023 | PressReach (Ad)
Stocks Positioned For The Year
This breakthrough stock has bright future this decade.
September 17, 2022 | cnet.com
2023 Lexus RX First Drive Review: Turbo? Hybrid? Why Not Both?
September 14, 2022 | finance.yahoo.com
BioSyent to Present at the Virtual MicroCap Leadership Summit
August 24, 2022 | seekingalpha.com
BioSyent reports Q2 results
August 23, 2022 | nz.finance.yahoo.com
BioSyent Releases Q2 and H1 2022 Financial Results
August 23, 2022 | finance.yahoo.com
BioSyent Announces Adoption of Dividend Policy
July 6, 2022 | uk.finance.yahoo.com
Factors that could predict the future for shares in Biosyent
June 27, 2022 | uk.finance.yahoo.com
BioSyent (CVE:RX) shareholders have earned a 6.8% CAGR over the last three years
May 18, 2022 | globenewswire.com
BioSyent Releases Financial Results for Q1 2022 - GlobeNewswire
May 18, 2022 | finance.yahoo.com
BioSyent Releases Financial Results for Q1 2022 - Yahoo Finance
May 11, 2022 | finance.yahoo.com
BioSyent Schedules Q1 2022 Earnings Release for May 18, 2022 - Yahoo Finance
May 10, 2022 | globenewswire.com
BioSyent Schedules Q1 2022 Earnings Release for May 18, 2022 - GlobeNewswire
May 2, 2022 | finance.yahoo.com
FeraMAX® Named #1 Recommended Iron Supplement in Canada by Pharmacists and Physicians for Seventh Consecutive Year - Yahoo Finance
April 28, 2022 | finance.yahoo.com
BioSyent to Present at 2022 Bloom Burton & Co. Healthcare Investor Conference - Yahoo Finance
April 26, 2022 | globenewswire.com
BioSyent to Present at 2022 Bloom Burton & Co. Healthcare Investor Conference - GlobeNewswire
April 3, 2022 | au.finance.yahoo.com
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2021
March 31, 2022 | globenewswire.com
BioSyent Announces Grant of Restricted Share Units - GlobeNewswire
March 29, 2022 | finance.yahoo.com
FAX Capital Corp. Reports Fourth Quarter and 2021 Results - Yahoo Finance
March 9, 2022 | globenewswire.com
BioSyent Releases Financial Results for Fourth Quarter and Full Year 2021 - GlobeNewswire
See More Headlines
Receive RX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BioSyent and its competitors with MarketBeat's FREE daily newsletter.

RX Company Calendar

Last Earnings
5/25/2017
Today
3/21/2023
Next Earnings (Estimated)
3/22/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
CVE
Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
CVE:RX
CUSIP
N/A
CIK
N/A
Web
www.biosyent.com
Phone
+1-905-2060013
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
C$0.49
Trailing P/E Ratio
14.86
Forward P/E Ratio
13.83
P/E Growth
N/A
Net Income
C$6.14 million
Net Margins
22.17%
Pretax Margin
N/A
Return on Equity
19.38%
Return on Assets
13.03%

Debt

Debt-to-Equity Ratio
4.36
Current Ratio
7.93
Quick Ratio
6.91

Sales & Book Value

Annual Sales
C$27.68 million
Price / Sales
3.18
Cash Flow
C$2.37 per share
Price / Cash Flow
3.07
Book Value
C$2.71 per share
Price / Book
2.69

Miscellaneous

Outstanding Shares
12,100,000
Free Float
N/A
Market Cap
C$88.09 million
Optionable
Not Optionable
Beta
0.78

Key Executives

  • Mr. René C. Goehrum (Age 64)
    Chairman, CEO & Pres
    Comp: $542.38k
  • Mr. Robert J. March
    VP of Fin. & CFO
  • Mr. Joost van der Mark
    VP of Corp. Devel.
  • Ms. Neelu Atwal
    Director of HR
  • Mr. Alfred D'Souza
    Advisor

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













RX Stock - Frequently Asked Questions

How have RX shares performed in 2023?

BioSyent's stock was trading at C$7.00 at the beginning of 2023. Since then, RX stock has increased by 4.0% and is now trading at C$7.28.
View the best growth stocks for 2023 here.

When is BioSyent's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 22nd 2023.
View our RX earnings forecast.

How were BioSyent's earnings last quarter?

BioSyent Inc. (CVE:RX) announced its quarterly earnings data on Thursday, May, 25th. The company reported $0.06 earnings per share for the quarter, missing the consensus estimate of $0.08 by $0.02. The company earned $3.82 million during the quarter, compared to the consensus estimate of $4.80 million. BioSyent had a net margin of 22.17% and a trailing twelve-month return on equity of 19.38%.

Is BioSyent a good dividend stock?

BioSyent (CVE:RX) pays an annual dividend of C$0.16 per share and currently has a dividend yield of 2.24%. The dividend payout ratio is 32.65%. This payout ratio is at a healthy, sustainable level, below 75%.

What other stocks do shareholders of BioSyent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BioSyent investors own include Aurora Cannabis (ACB), Canadian National Railway (CNR), Bank of Nova Scotia (BNS), Cross Timbers Royalty Trust (CRT), Dollarama (DOL), Enbridge (ENB), Gilead Sciences (GILD), National Bank of Canada (NA) and Air Canada (AC).

What is BioSyent's stock symbol?

BioSyent trades on the Canadian Venture Exchange (CVE) under the ticker symbol "RX."

How do I buy shares of BioSyent?

Shares of RX stock and other Canadian stocks can be purchased through an online brokerage account. Popular online brokerages with access to the Canadian stock market include BMO InvestorLine, CIBC Investor's Edge, Desjardins Online Brokerage, HSBC InvestDirect, Laurentian Bank Discount Brokerage, National Bank Direct Brokerage, Qtrade Investor, Questrade, RBC Direct Investing, Scotia iTrade, TD Direct Investing, and Virtual Brokers.
Compare Top Brokerages Here.

What is BioSyent's stock price today?

One share of RX stock can currently be purchased for approximately C$7.28.

How much money does BioSyent make?

BioSyent (CVE:RX) has a market capitalization of C$88.09 million and generates C$27.68 million in revenue each year. The company earns C$6.14 million in net income (profit) each year or C$0.49 on an earnings per share basis.

How can I contact BioSyent?

BioSyent's mailing address is 170 Attwell Dr Suite 520, ETOBICOKE, ON M9W 5Z5, Canada. The official website for the company is www.biosyent.com. The company can be reached via phone at +1-905-2060013.

This page (CVE:RX) was last updated on 3/21/2023 by MarketBeat.com Staff